In this study, we demonstrated in a large cohort of patients with MASLD that CD34 staining, representing LSEC capillarisation, appears already at the stage of MASL – hence before MASH onset – and increases with the severity of MASLD, being strongly linked to liver fibrosis, and to a lesser extent to liver inflammation, and that it regresses following treatment with the pan-PPAR agonist lanifibranor.33 Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.